# OnCo record nct07610525 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07610525/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07610525", "NCT07610525" ;
  schema:name "Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial"@en ;
  schema:description "A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin and pembrolizumab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07610525/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07610525> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pembrolizumab/> .
